Page 196 - 18F-FDG PET as biomarker in aggressive lymphoma; technical and clinical validation

Chapter 7
References
1. Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375-2390.
2. Ziepert M, Hasenclever D, Kuhnt E, et al. Standard International prognostic index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era. J Clin Oncol. 2010;28(14):2373-2380.
3. Lenz G, Wright GW, Emre NC, et al. Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways. Proc Natl Acad Sci U S A. 2008;105(36):13520-13525.
4. AukemaSM,KreuzM,KohlerCW,etal.BiologiccharacterizationofadultMYCtranslocationpositive mature B-cell lymphomas other than molecular Burkitt lymphoma. Haematologica. 2014;99(4):726- 735.
5. Oki Y, Noorani M, Lin P, et al. Double hit lymphoma: the MD Anderson Cancer Center clinical experience. Br J Haematol. 2014;166(6):891-901.
6. Savage KJ, Johnson NA, Ben-Neriah S, et al. MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy. Blood. 2009;114(17):3533-3537.
7. Rosenwald A, Bens S, Advani R, et al. Prognostic significance of MYC rearrangement and translocation partner in diffuse large B-cell lymphoma: a study by the Lunenburg Lymphoma Biomarker Consortium. J Clin Oncol. 2019;37(35):3359-3368.
8. Barrans S, Crouch S, Smith A, et al. Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab. J Clin Oncol. 2010;28(20):3360-3365.
9. Howlett C, Snedecor SJ, Landsburg DJ, et al. Front-line,dose-escalated immunochemotherapy is associated with a significant progression-free survival advantage in patients with double-hit lymphomas: a systematic review and meta-analysis. Br J Haematol. 2015; 170(4):504-514.
10. Petrich AM, Gandhi M, Jovanovic B, et al. Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis. Blood. 2014;124(15):2354- 2361.
11. Landsburg DJ, Falkiewicz MK, Maly J, et al. Outcomes of patients with double hit lymphoma who achieve first complete remission. J Clin Oncol. 2017;35(20):2260-2267.
12. Dunleavy K, Fanale MA, Abramson JS, et al. Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, multicentre, single-arm phase 2 study. Lancet Haematol. 2018;5(12):e609-e617.
13. WitzigTE,WiernikPH,MooreT,etal.Lenalidomideoralmonotherapyproducesdurableresponses in relapsed or refractory indolent non-Hodgkin’s Lymphoma. J Clin Oncol. 2009;27(32):5404-5409.
14. Lopez-Girona A, Heintel D, Zhang LH, et al. Lenalidomide downregulates the cell survival factor, interferon regulatory factor-4, providing a potential mechanistic link for predicting response. Br J Haematol. 2011; 154(3):325-336.
15. Ayed AO, Chiappella A, Pederson L, et al. CNS relapse in patients with DLBCL treated with lenalidomide plus R-CHOP (R2CHOP): analysis from two phase 2 studies. Blood Cancer J. 2018;8(7):63.
16. Castellino A, Chiappella A, LaPlant BR, et al. Lenalidomide plus R-CHOP21 in newly diagnosed diffuse large B-cell lymphoma (DLBCL): long-term follow-up results from a combined analysis from two phase 2 trials. Blood Cancer J. 2018;8(11):108.
17. Vitolo U, Witzig TE, Gascoyne RD, et al. ROBUST: first report of phase III randomized study of lenalidomide/R-CHOP (R2- CHOP) vs placebo/R-CHOP in previously untreated ABC-type diffuse large B-cell lymphoma. Haematol Oncol. 2019;37(52):36-37.
18. Chamuleau M, Nijland M, Lamers N, et al. First Report on a successful screening program for MYC rearrangements and a prospective clinical trial based on MYC rearrangement in newly diagnosed DLBCL patients in the Netherlands. Blood. 2017; 130(Supplement 1):4144.
194